Mona Steinbügl
YOU?
Author Swipe
View article: Supplementary Figure S1 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Figure S1 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Supplementary Figure 1: (A) Venn diagram displaying which patients clinical data were previously published in Nemes et al. 2022. (B) Cumulative distribution functions (CDF) of the consensus matrix for each k. (C-E) Histograms for k=2, k=3,…
View article: Supplementary Figure S2 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Figure S2 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
t-stochastic neighbor embedding (tSNE) plot displaying the DNA methylation of the three atypical teratoid rhabdoid tumor (ATRT) subgroups and the three extracranial malignant rhabdoid tumors (eMRT) subgroups. Triangles indicate which sampl…
View article: Supplementary Figure S5 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Figure S5 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Random forest predictor for eMRT subgroups based on DNA methylation-an example
View article: Supplementary Table S5 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Table S5 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
CpG Sites used for model generation
View article: Supplementary Figure S3 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Figure S3 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Copy number alterations for extracranial malignant rhabdoid tumors
View article: Supplementary Table S3 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Table S3 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Cox-Regression model
View article: Supplementary Table S4 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Table S4 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Relapse therapy overview
View article: Supplementary Table S2 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Table S2 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Results of differential gene expression analysis
View article: Supplementary Table S1 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Table S1 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Cohort overview
View article: Data from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Data from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Purpose:Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55% to 67% of these. Molecular markers for identification of patients at increase…
View article: Supplementary Figure S4 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors
Supplementary Figure S4 from Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors Open
Supplementary Figure 4: Mean methylation of the primary and relapsed or refractory tumors for five patients.
View article: ATRT-04. RETROSPECTIVE ANALYSIS OF 271 RELAPSED AND REFRACTORY ATYPICAL TERATOID RHABDOID TUMORS – COMBING DATA FROM INTERNATIONAL COHORTS IN A COLLABORATIVE EFFORT
ATRT-04. RETROSPECTIVE ANALYSIS OF 271 RELAPSED AND REFRACTORY ATYPICAL TERATOID RHABDOID TUMORS – COMBING DATA FROM INTERNATIONAL COHORTS IN A COLLABORATIVE EFFORT Open
BACKGROUND Relapse or refractory (r/r) disease is common in atypical teratoid rhabdoid tumors (ATRT), yet little is known about clinical patterns, prognostic factors, and outcomes beyond individual case reports. Large representative cohort…
View article: ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population
ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population Open
INTRODUCTION: Malignant rhabdoid tumors (MRT) predominantly affect infants. Patients below six months represent a particularly challenging group: intensity of therapy is limited by toxicity to developing organs. Information on prognostic f…
View article: ATRT-14. Malignant rhabdoid tumors of cranial nerves – ATRT or extracranial rhabdoid tumor?
ATRT-14. Malignant rhabdoid tumors of cranial nerves – ATRT or extracranial rhabdoid tumor? Open
INTRODUCTION: Malignant rhabdoid tumors (MRT) are highly aggressive neoplasias mostly affecting young children. They are classified as rhabdoid tumors of the central nervous system (ATRT, atypical teratoid rhabdoid tumor), rhabdoid tumors …
View article: ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT – The EU-RHAB perspective
ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT – The EU-RHAB perspective Open
Currently an internationally accepted consensus treatment for relapsed/refractory ATRT is missing. Little is known about relapse patterns, prognostic factors and outcome. In a recently published cohort of 143 ATRTs from the EU-RHAB registr…
View article: NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) – Finding Evidence by systematic Analyses
NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) – Finding Evidence by systematic Analyses Open
BACKGROUND: Individuals with rhabdoid tumor predisposition syndrome (RTPS1 – SMARCB1, RTPS2 – SMARCA4) have a propensity to develop malignant rhabdoid tumors (MRT). Affected patients typically present < age 12 months with synchronous tu…
View article: Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population
Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population Open
Introduction: Malignant rhabdoid tumors (MRT) predominantly affect infants and young children. Patients below six months of age represent a particularly therapeutically challenging group. Toxicity to developing organ sites limits intensity…
View article: Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors Open
Background Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has main…
View article: Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors Open
Background Controversy exists as to what may be defined as standard of care (including markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The European Rhabdoid Registry (EU-RHAB) recruits uniformly tre…